Kinase Targeting for Neurodegenerative Diseases

Kinase Targeting for Neurodegenerative Diseases

Overview

Protein kinases represent one of the most promising therapeutic target classes for neurodegenerative diseases. Kinases regulate critical cellular processes including endolysosomal trafficking, neuroinflammation, mitochondrial homeostasis, and protein quality control systems—all of which are frequently dysregulated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [multiple sclerosis](/diseases/multiple-sclerosis).

This mechanism page synthesizes the current state of kinase-targeted drug development for neurodegenerative disorders, based on the comprehensive review by Shomali and Trempe in Pharmacology Reviews (2026) PMID: 41880688(https://pubmed.ncbi.nlm.nih.gov/41880688/)].

Key Kinase Families in Neurodegeneration

Cyclin-Dependent Kinase 5 (CDK5)

CDK5 is a proline-directed serine/threonine kinase activated by binding partners p35 or p39. It plays a critical role in neuronal development and synaptic function, but dysregulated CDK5 activity contributes to tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer's disease.

Role in Disease:

• Phosphorylates tau at multiple sites associated with NFT formation
• Regulates amyloid precursor protein (APP) processing
• Controls synaptic vesicle trafficking
• Contributes to neuronal death through p53 activation

Kinase Targeting for Neurodegenerative Diseases

Overview

Protein kinases represent one of the most promising therapeutic target classes for neurodegenerative diseases. Kinases regulate critical cellular processes including endolysosomal trafficking, neuroinflammation, mitochondrial homeostasis, and protein quality control systems—all of which are frequently dysregulated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [multiple sclerosis](/diseases/multiple-sclerosis).

This mechanism page synthesizes the current state of kinase-targeted drug development for neurodegenerative disorders, based on the comprehensive review by Shomali and Trempe in Pharmacology Reviews (2026) PMID: 41880688(https://pubmed.ncbi.nlm.nih.gov/41880688/)].

Key Kinase Families in Neurodegeneration

Cyclin-Dependent Kinase 5 (CDK5)

CDK5 is a proline-directed serine/threonine kinase activated by binding partners p35 or p39. It plays a critical role in neuronal development and synaptic function, but dysregulated CDK5 activity contributes to tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer's disease.

Role in Disease:

• Phosphorylates tau at multiple sites associated with NFT formation
• Regulates amyloid precursor protein (APP) processing
• Controls synaptic vesicle trafficking
• Contributes to neuronal death through p53 activation

• Inhibitors: Roscovitine, Flavopiridol (pan-CDK inhibitors with limited brain penetration)
• Allosteric inhibitors targeting CDK5-p35 interaction
• Prodrugs designed to cross the blood-brain barrier

• CDK5 knockdown reduces tau pathology in 3xTG-AD mice
• p25 transgenic mice show CDK5 hyperactivation with enhanced tau pathology
• Neuroprotective effects in multiple animal models

Glycogen Synthase Kinase 3 (GSK3)

GSK3 exists as two isoforms: GSK3α and GSK3β. It is a multifunctional serine/threonine kinase involved in numerous cellular processes including glycogen metabolism, gene transcription, and apoptosis. GSK3β is particularly implicated in Alzheimer's disease pathogenesis.

Role in Disease:

• Phosphorylates tau at multiple pathogenic sites (Ser396, Ser404, Thr181)
• Regulates amyloid-β production through APP processing
• Promotes inflammatory responses via NF-κB activation
• Contributes to synaptic dysfunction

• ATP-competitive inhibitors: Tideglusib, SB-216763
• Isoform-selective inhibitors under development
• Lithium (indirect GSK3 inhibition via upstream mechanisms)

• Tideglusib (NP-12): Completed Phase II trials in AD with mixed results
• Lithium: Ongoing trials for AD and ALS

Leucine-Rich Repeat Kinase 2 (LRRK2)

LRRK2 is a large ROCO kinase with GTPase and kinase domains. Gain-of-function mutations are the most common genetic cause of familial Parkinson's disease (G2019S, R1441C/H/G).

Role in Disease:

• Regulates endolysosomal trafficking and autophagy
• Controls mitochondrial dynamics and quality control
• Modulates inflammatory responses in microglia
• Affects synaptic function and dopamine neuron survival

• ATP-competitive inhibitors: DNL151 (Denali), GLC-474 (Genentech)
• Brain-penetrant compounds in clinical development
• Allosteric inhibitors targeting the kinase domain

• DNL151: Completed Phase I, showed target engagement
• BIIB122 (DNL151): Phase II trials in PD (LBP-PD)
• GLC-474: Preclinical/Phase I

PTEN-Induced Kinase 1 (PINK1)

PINK1 is a serine/threonine-protein kinase that acts as a master regulator of mitophagy. Loss-of-function mutations cause early-onset familial Parkinson's disease.

Role in Disease:

• Recruits Parkin to damaged mitochondria
• Phosphorylates ubiquitin and Parkin to activate mitophagy
• Protects against oxidative stress
• Maintains mitochondrial integrity

• Activators of PINK1-Parkin pathway
• Small molecules stabilizing PINK1 on mitochondrial outer membrane
• Gene therapy approaches

• PINK1 knockin mice show mitochondrial dysfunction
• Adenoviral PINK1 delivery protects against MPTP toxicity
• Phosphomimetic Parkin shows enhanced mitophagy

p38 Mitogen-Activated Protein Kinases (MAPKs)

The p38 MAPK family (α, β, γ, δ isoforms) mediates cellular stress responses and inflammatory signaling. p38α is the most studied in neurodegeneration.

Role in Disease:

• Mediates cytokine production in microglia (IL-1β, TNF-α)
• Promotes neuronal apoptosis under stress conditions
• Contributes to blood-brain barrier dysfunction
• Regulates tau pathology through kinase activation

• p38α inhibitors: Losmapimod, Pamapimod
• Brain-penetrant compounds under development
• Anti-inflammatory strategies

• Losmapimod: Tested in AD and ALS (Phase II)
• Mixed results due to limited efficacy and safety concerns

Bruton's Tyrosine Kinase (BTK)

BTK is a non-receptor tyrosine kinase involved in B-cell receptor signaling and myeloid cell activation. It has emerged as a novel target for neurodegenerative diseases.

Role in Disease:

• Regulates microglial activation and neuroinflammation
• Controls B-cell mediated autoimmune responses relevant to MS
• Modulates phagocytosis in myeloid cells
• Involved in TLR signaling

• BTK inhibitors: Tolebrutinib (SAR442168), Evobrutinib
• Central nervous system-penetrant compounds

• Tolebrutinib: Phase II/III trials in MS (peripheral and CNS effects)
• Evobrutinib: Tested in MS and AD

c-Abl (ABL1)

c-Abl is a non-receptor tyrosine kinase involved in cell growth, differentiation, and stress responses. It is activated in Alzheimer's and Parkinson's disease brains.

Role in Disease:

• Promotes tau phosphorylation and aggregation
• Activates autophagy pathways (both beneficial and pathological)
• Contributes to mitochondrial dysfunction
• Mediates oxidative stress responses

• ATP-competitive inhibitors: Imatinib (approved for CML)
• Brain-penetrant second-generation inhibitors
• Allosteric inhibitors

• Imatinib showed neuroprotective effects in preclinical models
• Safety established but efficacy in neurodegeneration unclear
• Second-generation compounds under development

c-Jun N-terminal Kinases (JNKs)

JNK family members (JNK1, JNK2, JNK3) mediate stress-activated signaling pathways. JNK3 is neuron-specific and particularly implicated in neurodegeneration.

Role in Disease:

• Phosphorylates tau at pathological sites
• Mediates excitotoxicity-induced neuronal death
• Regulates transcription of pro-apoptotic genes
• Controls synaptic plasticity

• JNK3-selective inhibitors
• Peptide inhibitors targeting JNK interaction domains
• Brain-penetrant small molecules

• JNK3 knockout mice show neuroprotection
• SP600125 (pan-JNK inhibitor) shows efficacy in PD models

Kinase Interactions in Neurodegeneration

Therapeutic Strategy Comparison

| Kinase | Disease Focus | Drug Candidates | Development Stage | Key Challenge |
|--------|---------------|------------------|-------------------|----------------|
| CDK5 | AD, PD | Roscovitine | Preclinical | Brain penetration |
| GSK3α/β | AD | Tideglusib | Phase II | Safety, efficacy |
| LRRK2 | PD | DNL151, GLC-474 | Phase II | Selectivity |
| PINK1 | PD | Gene therapy | Preclinical | Delivery |
| p38α | AD, MS | Losmapimod | Phase II | Efficacy |
| BTK | MS, AD | Tolebrutinib | Phase II/III | CNS activity |
| c-Abl | PD | Imatinib | Phase II | Brain penetration |
| JNK3 | AD, PD | SP600125 | Preclinical | Isoform selectivity |

Challenges in Kinase-Targeted Therapy

Selectivity

Kinases share highly conserved ATP-binding pockets, making selective inhibition challenging. Off-target effects lead to toxicity and limit therapeutic window. Strategies to improve selectivity include:

• Targeting allosteric sites unique to each kinase
• Developing isoform-selective inhibitors
• Using covalent inhibitors for irreversible targeting

Brain Penetration

The blood-brain barrier (BBB) excludes most kinase inhibitors. Current approaches include:

• Designing compounds with optimal physicochemical properties (MW < 400, LogP 2-4)
• Using prodrug strategies
• Targeting transporter-mediated uptake
• Intranasal delivery systems

Target Validation

Many kinase inhibitors show preclinical promise but fail in clinical trials due to:

• Incomplete understanding of disease-relevant pathways
• Compensatory mechanisms negating kinase inhibition
• Inadequate biomarkers for target engagement
• Insufficient patient stratification

Cross-Disease Kinase Targets

Common Mechanisms

Several kinases are implicated across multiple neurodegenerative conditions:

Disease-Specific Targets

• Alzheimer's: CDK5, GSK3, p38, JNK
• Parkinson's: LRRK2, PINK1, c-Abl, JNK
• Multiple Sclerosis: BTK, p38

Conclusion and Future Directions

Kinase targeting represents a promising but challenging therapeutic strategy for neurodegenerative diseases. Key success factors include:

The ongoing clinical trials for LRRK2 and BTK inhibitors represent critical tests for the entire field of kinase-targeted neurodegeneration therapy.

References